팔로우
Brandon Piel
Brandon Piel
Dana-Farber Cancer Institute
dfci.harvard.edu의 이메일 확인됨
제목
인용
인용
연도
Cancer nanomedicine: a review of recent success in drug delivery
PR Stephanie Tran, Peter-Joseph DeGiovanni, Brandon Piel
Clinical and Translational Medicine 6 (44), 2017
9182017
Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer
S Kitajima, E Ivanova, S Guo, R Yoshida, M Campisi, SK Sundararaman, ...
Cancer discovery 9 (1), 34-45, 2019
3282019
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
I Cañadas, R Thummalapalli, JW Kim, S Kitajima, RW Jenkins, ...
Nature medicine 24 (8), 1143-1150, 2018
2442018
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade
AR Aref, M Campisi, E Ivanova, A Portell, D Larios, BP Piel, N Mathur, ...
Lab on a Chip 18 (20), 3129-3143, 2018
2142018
Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity
NR Mahadevan, EH Knelson, JO Wolff, A Vajdi, M Saigí, M Campisi, ...
Cancer discovery 11 (8), 1952-1969, 2021
932021
Nanoparticle design strategies for effective cancer immunotherapy
P Velpurisiva, A Gad, B Piel, R Jadia, P Rai
Journal of Biomedicine (Sydney, NSW) 2 (2), 64, 2017
682017
Targeting cancer using polymeric nanoparticle mediated combination chemotherapy
A Gad, J Kydd, B Piel, P Rai
International journal of nanomedicine and nanosurgery 2 (3), 2016
592016
Tumor-derived cGAMP regulates activation of the vasculature
M Campisi, SK Sundararaman, SE Shelton, EH Knelson, NR Mahadevan, ...
Frontiers in Immunology 11, 2090, 2020
472020
Phosphorylation of Rab7 by TBK1/IKKϵ regulates innate immune signaling in triple-negative breast cancer
JL Ritter, Z Zhu, TC Thai, NR Mahadevan, P Mertins, EH Knelson, BP Piel, ...
Cancer research 80 (1), 44-56, 2020
402020
Engineering remotely triggered liposomes to target triple negative breast cancer
A Sneider, R Jadia, B Piel, D VanDyke, C Tsiros, P Rai
Oncomedicine 2, 1, 2017
332017
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
S Kitajima, T Tani, BF Springer, M Campisi, T Osaki, K Haratani, M Chen, ...
Cancer Cell 40 (10), 1128-1144. e8, 2022
302022
Activation of tumor-cell STING primes NK-cell therapy
EH Knelson, EV Ivanova, M Tarannum, M Campisi, PH Lizotte, MA Booker, ...
Cancer immunology research 10 (8), 947-961, 2022
282022
Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discov. 2019; 9 (1): 34–45. doi: 10.1158/2159-8290
S Kitajima, E Ivanova, S Guo, R Yoshida, M Campisi, SK Sundararaman, ...
CD-18-0689.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
21
Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017; 6: 44
S Tran, PJ DeGiovanni, B Piel, P Rai
14
Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017; 6 (1): 44
S Tran, PJ DeGiovanni, B Piel, P Rai
13
Liposomes aid curcumin's combat with cancer in a breast tumor model
R Jadia, J Kydd, B Piel, P Rai
Oncomedicine 3, 94-109, 2018
112018
GSK461364A, a polo-like kinase-1 inhibitor encapsulated in polymeric nanoparticles for the treatment of glioblastoma multiforme (GBM)
P Velpurisiva, BP Piel, J Lepine, P Rai
Bioengineering 5 (4), 83, 2018
102018
development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC)
Y Wang, A Buck, M Grimaud, S Kodangattil, C Razimbaud, A Fayed, ...
Cancer Research 81 (13_Supplement), 62-62, 2021
22021
fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects
Y Wang, A Buck, G Kastrunes, R Abbas, M Lynch, Z Zhong, SM Hoang, ...
Cancer Research 83 (7_Supplement), 886-886, 2023
12023
295 Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects
Y Wang, A Buck, M Lynch, G Kastrunes, JW Cho, M Grimaud, D Braun, ...
Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022
12022
현재 시스템이 작동되지 않습니다. 나중에 다시 시도해 주세요.
학술자료 1–20